摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 3-((6-nitropyridin-3-yl)oxy)azetidine-1-carboxylate | 1346674-71-2

中文名称
——
中文别名
——
英文名称
tert-butyl 3-((6-nitropyridin-3-yl)oxy)azetidine-1-carboxylate
英文别名
tert-Butyl 3-(6-Nitropyridin-3-yloxy)azetidine-1-carboxylate;tert-butyl 3-(6-nitropyridin-3-yl)oxyazetidine-1-carboxylate
tert-butyl 3-((6-nitropyridin-3-yl)oxy)azetidine-1-carboxylate化学式
CAS
1346674-71-2
化学式
C13H17N3O5
mdl
——
分子量
295.295
InChiKey
FWFBNCGICPGVFQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    453.8±45.0 °C(Predicted)
  • 密度:
    1.319±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    21
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    97.5
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] P300/CBP HAT INHIBITORS AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE P300/CBP HAT ET LEURS PROCÉDÉS D'UTILISATION
    申请人:CONSTELLATION PHARMACEUTICALS INC
    公开号:WO2020176558A1
    公开(公告)日:2020-09-03
    Provided are compounds of Formula (I) : and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).
    提供的是化合物的化学式(I):及其药用可接受的盐和组合物,用于治疗与组蛋白乙酰转移酶(HAT)相关的各种疾病。
  • HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS
    申请人:Genentech, Inc.
    公开号:US20140194408A1
    公开(公告)日:2014-07-10
    Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X 1 , X 2 , and X 3 are N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    本发明提供了式I的杂环吡啶酮和杂环氮杂吡啶酮化合物,其中X1、X2和X3中的一个或两个为N,包括立体异构体、互变异构体和药学上可接受的盐,用于抑制Btk激酶并治疗由Btk激酶介导的免疫障碍,如炎症。本发明还揭示了使用式I化合物进行哺乳动物细胞中的体外、原位和体内诊断和治疗此类障碍或相关病理条件的方法。
  • HETEROARYL PYRIDONE AND AZA-PYRODINE COMPOUNDS
    申请人:Genentech, Inc.
    公开号:US20160228432A1
    公开(公告)日:2016-08-11
    Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    本发明提供了杂环芳基吡啶酮和氮杂芳基吡啶酮化合物,包括立体异构体、互变异构体和其药学上可接受的盐,用于抑制Btk激酶,并用于治疗由Btk激酶介导的免疫紊乱,如炎症。本发明揭示了使用杂环芳基吡啶酮和氮杂芳基吡啶酮化合物进行体外、体内和原位诊断和治疗哺乳动物细胞中的这种紊乱或相关病理条件的方法。
  • PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE
    申请人:BARBOSA Antonio J.M.
    公开号:US20120010191A1
    公开(公告)日:2012-01-12
    Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    本发明提供公式I的吡啶酮和氮杂吡啶酮化合物,包括立体异构体、互变异构体和其医药上可接受的盐,用于抑制Btk激酶并治疗由Btk激酶介导的免疫紊乱,例如炎症。本发明还公开了使用公式I化合物在哺乳动物细胞中进行体外、原位和体内诊断和治疗此类疾病或相关病理条件的方法。
  • Heteroaryl pyridone and aza-pyridone compounds
    申请人:Genentech, Inc.
    公开号:US08716274B2
    公开(公告)日:2014-05-06
    Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X1, X2, and X3 are N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    提供了公式I的杂环吡啶酮和氮杂吡啶酮化合物,其中X1、X2和X3中的一个或两个为N,包括立体异构体、互变异构体和药学上可接受的盐,用于抑制Btk激酶并治疗由Btk激酶介导的免疫紊乱,如炎症。公开了使用公式I化合物进行哺乳动物细胞中的体外、原位和体内诊断和治疗这种疾病或相关病理条件的方法。
查看更多